PDPN and cancer: In this review article, we will outline the application of cancer immunotherapy using CTLs with incorporated antigen recognition receptors and explain the possibility of the clinical application of chimeric antigen receptor (CAR) T cell therapies that target the mucin-type glycoprotein, podoplanin (PDPN), and finally the possibility of using CAR T cell therapies that would leverage the new technology of induced pluripotent stem (iPS) cells.